Anti-Xa trough levels for therapeutic LMWH treatment monitoring, a pilot study

Completed

• Conditions: VTE venous tromboembolic events en Atriumfibrillation; 10014523

• Registration Number: NL-OMON49087
• Lead Sponsor: Sint Antonius Ziekenhuis

Brief Summary

Not available

Detailed Description

Not available

Study Timeline

• Last Update Posted: 15 April 2024

Recruitment & Eligibility

• Status: Completed
• Sex: Not specified
• Target Recruitment: 30

Inclusion Criteria

Adult hospitalized patients receiving nadroparin in therapeutic doses for a
period of *3days, written informed consent.

Exclusion Criteria

Patients on CVVH, peritoneal dialysis, or ECMO. Patients with congenital
coagulation disorders.

Study & Design

• Study Type: Observational invasive
• Study Design: Not specified

Primary Outcome Measures

Name	Time	Method
<p>The primary study parameter consists of mean anti-Xa trough- and peak levels<br /><br>per subgroup, presented as mean ± standard deviation (or as median and ranges<br /><br>if data is not normally distributed, which will be tested in IBM SPSS). </p><br>

Secondary Outcome Measures

Name	Time	Method
<p>Anti-Xa trough and peak levels related to creatinine clearance and bodyweight<br /><br>presented per subgroup as mean ± standard deviation (or as median and ranges if<br /><br>data is not normally distributed, which will be tested in IBM SPSS).</p><br>